China / Edigene CEO on Gene Editing Biotech’s Ambitious Expansion Plans
Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and therapies as it becomes a clinical-phase company.…